Search Results - "Armstrong, April W."

Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment.

Authors: Armstrong, April W. Bin Sawad, Aseel Hazra, Nisha C. et al.

Source: Dermatology & Therapy. Jun2026, p1-21. 21p.

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis.

Authors: Armstrong, April W. Burne, Rebecca Bin Sawad, Aseel et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p3013-3026. 14p.

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

Authors: Elbuluk, Nada Armstrong, April W. Vender, Ronald et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p3215-3234. 20p.

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.

Authors: Armstrong, April W. Krueger, James G. Strober, Bruce E. et al.

Source: Dermatology & Therapy. Jun2026, Vol. 16 Issue 6, p2661-2673. 13p.

Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis.

Authors: Armstrong, April W. Warren, Richard B. Sofen, Howard et al.

Source: Dermatology & Therapy. Jan2026, Vol. 16 Issue 1, p637-646. 10p.

Is Cumulative Life Course Impairment Considered in Psoriasis Management? A Multinational Survey of People with Psoriasis and Healthcare Professionals.

Authors: Matthews, Raymond Armstrong, April W. Augustin, Matthias et al.

Source: Dermatology & Therapy. Jan2026, Vol. 16 Issue 1, p499-520. 22p.

Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry.

Authors: Armstrong, April W. Feldman, Steven R. Fitzgerald, Timothy et al.

Source: Dermatology & Therapy. Aug2025, Vol. 15 Issue 8, p2117-2130. 14p.

Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials.

Authors: Armstrong, April W. Kircik, Leon Stein Gold, Linda et al.

Source: Dermatology & Therapy. Apr2025, Vol. 15 Issue 4, p1025-1035. 11p.

Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.

Authors: Armstrong, April W. Augustin, Matthias Beaumont, Jennifer L. et al.

Source: Dermatology & Therapy. Apr2025, Vol. 15 Issue 4, p1037-1044. 8p.

Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis.

Authors: Papp, Kim A. Armstrong, April W. Koresawa, Tomokazu et al.

Source: Journal of the European Academy of Dermatology & Venereology. Apr2026, Vol. 40 Issue 4, p610-616. 7p.

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis.

Authors: Armstrong, April W. Soliman, Ahmed M. Gisondi, Paolo et al.

Source: Dermatology & Therapy. Nov2024, Vol. 14 Issue 11, p3071-3081. 11p.

Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.

Authors: Lebwohl, Mark G. Armstrong, April W. Alexis, Andrew F. et al.

Source: Dermatology & Therapy. Oct2024, Vol. 14 Issue 10, p2709-2726. 18p.

Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.

Authors: Armstrong, April W. Foley, Peter Liu, Yan et al.

Source: Dermatology & Therapy. Sep2024, Vol. 14 Issue 9, p2577-2589. 13p.

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis.

Authors: Armstrong, April W. Hong, H. Chih-Ho Calimlim, Brian M. et al.

Source: Dermatology & Therapy. Sep2024, Vol. 14 Issue 9, p2457-2465. 9p.

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.

Authors: Armstrong, April W. Augustin, Matthias Beaumont, Jennifer L. et al.

Source: Dermatology & Therapy. Aug2024, Vol. 14 Issue 8, p2235-2248. 14p.

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.

Authors: Armstrong, April W. Park, Sang Hee Patel, Vardhaman et al.

Source: Dermatology & Therapy. Jul2024, Vol. 14 Issue 7, p1891-1899. 9p.

Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.

Authors: Armstrong, April W. Alexis, Andrew F. Blauvelt, Andrew et al.

Source: Dermatology & Therapy. Jul2024, Vol. 14 Issue 7, p1849-1861. 13p.

Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.

Authors: Armstrong, April W. Jaleel, Tarannum Merola, Joseph F. et al.

Source: Dermatology & Therapy. Jun2024, Vol. 14 Issue 6, p1615-1631. 17p.

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.

Authors: Armstrong, April W. Jayade, Sayeli Rege, Sanika et al.

Source: Dermatology & Therapy. Feb2024, Vol. 14 Issue 2, p421-439. 19p.

Abstracts from the 7^th IFPA Conference World Psoriasis & Psoriatic Arthritis Conference 27-29 June, 2024.

Authors: Armstrong, April W.¹

Source: Acta Dermato-Venereologica. 2024, Vol. 104, p1-98. 99p.